Webinar explores how GLP-1 obesity drugs are reshaping US healthcare and market dynamics

The upcoming webinar titled "The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets" will examine how GLP-1 receptor agonists used for obesity are altering the U.S. health-care landscape.

Organizers note that distribution channels are shifting, with more direct-to-consumer portals and new pharmacy agreements, sparking debates over pricing and insurance coverage.

The session highlights that Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide already generate billions in revenue and have received additional approvals for cardiovascular risk reduction and sleep-apnea treatment, respectively.

Ongoing research is also exploring the class for addiction, Alzheimer’s disease and cancer, suggesting a broader therapeutic impact.

Attendees will learn strategies for companies to stay patient-focused while capturing revenue opportunities in this rapidly expanding market.